In 1992, Romach and colleagues reported that dose escalation is not a attribute of lengthy-expression alprazolam buyers and that the majority of lengthy-term alprazolam consumers alter their initial pattern of normal use to one of symptom Regulate only when necessary.[seventy four]Atomoxetine has also been linked to some more significant Uncomforta